FDA greenlights Omeros’ Yartemlea: first TA‑TMA therapy approved

The U.S. FDA approved Omeros Corp.’s Yartemlea (narsoplimab) as the first treatment for hematopoietic stem cell transplant‑associated thrombotic microangiopathy (TA‑TMA). The decision establishes a regulatory precedent for a previously unmet, life‑threatening post‑transplant complication. The approval gives clinicians a targeted option for TA‑TMA, a condition with high morbidity and limited therapeutic choices, and provides Omeros with a commercial foothold in a rare‑disease niche.